Key Takeaways
- • FDA published a Request for Information (RFI) on May 12, 2026, soliciting stakeholder input on drug repurposing strategies to accelerate treatments for unmet medical needs, with a public comment deadline of June 11, 2026.
- • The agency identified five priority disease areas for repurposing consideration: metabolic, neurodegenerative, men's and women's health, substance use, and rare diseases, seeking validation and additional candidates from clinical and research communities.
- • Drug repurposing candidates must meet three specific criteria: scientific evidence of effectiveness for the new use, identical dosage forms and routes of administration to approved indications, and comparable safety profiles across patient populations.
- • Recent legislative momentum supports the initiative, including the Mikaela Naylon Give Kids a Chance Act (signed February 2026) reauthorizing NIH pediatric drug trial programs, and the prior MODERN Labeling Act (2020), which established mechanisms for updating generic drug labeling based on new clinical evidence.
- • The RFI timing presents strategic implications for the upcoming Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee Act (GDUFA) reauthorizations, signaling potential regulatory and legislative refinements to drug repurposing frameworks.
Summary
The FDA's May 12, 2026 Request for Information represents a structured institutional effort to systematize drug repurposing as a regulatory tool for addressing unmet medical needs. The RFI targets a specific economic and clinical problem: approved drugs lacking commercial incentive for new indication development despite potential clinical benefit. By inviting stakeholders to identify priority disease areas and specific drug candidates, the FDA is leveraging distributed knowledge from clinical practitioners, researchers, and patient communities to inform its repurposing strategy.
The agency's five proposed priority disease areas—metabolic, neurodegenerative, men's and women's health, substance use, and rare diseases—reflect therapeutic areas where market forces alone may insufficient to justify the regulatory and commercial costs of seeking new indications. The three-part criteria framework (scientific evidence, matched dosage/route, comparable safety) establishes a pragmatic threshold for repurposing candidates, focusing on drugs where clinical repositioning does not require fundamental reformulation or novel safety investigations.
This initiative builds on established legislative foundations. The MODERN Labeling Act of 2020 created a formal mechanism for updating generic drug labeling to reflect current clinical practice and new evidence. More recently, Congress reaffirmed its support through the Mikaela Naylon Give Kids a Chance Act (February 2026), which reauthorized the NIH program sponsoring clinical trials of off-patent drugs in pediatric populations. The Make Our Children Healthy Again Strategy Report (September 2025) further directed the NIH and FDA to strengthen repurposed drug utilization while harmonizing clinical trial designs, signaling bipartisan consensus on the policy direction.
The June 11, 2026 comment deadline positions this RFI within broader regulatory reauthorization cycles. Input gathered through this process may inform the upcoming PDUFA and GDUFA reauthorizations, where Congress may codify additional repurposing frameworks or streamline approval pathways for relabeling of existing drugs. For institutional investors and alternative investment managers tracking pharmaceutical regulatory trends, the RFI signals sustained government momentum toward expanding the utility of existing drug assets and potentially reducing barriers to market entry for off-patent or low-margin therapeutic applications.
The agency's five proposed priority disease areas—metabolic, neurodegenerative, men's and women's health, substance use, and rare diseases—reflect therapeutic areas where market forces alone may insufficient to justify the regulatory and commercial costs of seeking new indications. The three-part criteria framework (scientific evidence, matched dosage/route, comparable safety) establishes a pragmatic threshold for repurposing candidates, focusing on drugs where clinical repositioning does not require fundamental reformulation or novel safety investigations.
This initiative builds on established legislative foundations. The MODERN Labeling Act of 2020 created a formal mechanism for updating generic drug labeling to reflect current clinical practice and new evidence. More recently, Congress reaffirmed its support through the Mikaela Naylon Give Kids a Chance Act (February 2026), which reauthorized the NIH program sponsoring clinical trials of off-patent drugs in pediatric populations. The Make Our Children Healthy Again Strategy Report (September 2025) further directed the NIH and FDA to strengthen repurposed drug utilization while harmonizing clinical trial designs, signaling bipartisan consensus on the policy direction.
The June 11, 2026 comment deadline positions this RFI within broader regulatory reauthorization cycles. Input gathered through this process may inform the upcoming PDUFA and GDUFA reauthorizations, where Congress may codify additional repurposing frameworks or streamline approval pathways for relabeling of existing drugs. For institutional investors and alternative investment managers tracking pharmaceutical regulatory trends, the RFI signals sustained government momentum toward expanding the utility of existing drug assets and potentially reducing barriers to market entry for off-patent or low-margin therapeutic applications.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.